Global Methicillin
Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product
(Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test and
Molecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories,
and Academic and Research Institute), and By Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be
valued at US$ 211.3 million in 2020 and is expected to exhibit a
CAGR of 10.5% during the forecast period (2020-2027), as highlighted in a new
report published by Coherent Market Insights.
The increasing number of product
approvals and launches, adoption of methicillin resistant staphylococcus aureus
(MRSA) testing systems, and mergers and acquisitions by key players are the
major factors that are expected to drive growth of the Methicillin Resistant
Staphylococcus Aureus (MRSA) Testing Systems market during the forecast period.
Product approvals by regulatory
bodies are expected drive growth of the methicillin resistant Staphylococcus
aureus (MRSA) testing systems market during the forecast period. For instance,
in December 2019, the US Food and Drug Administration (FDA) granted marketing
approval for Roche Molecular Systems’ cobas vivoDx MRSA, a diagnostic test that
detects colonisation of Methicillin-resistant Staphylococcus aureus (MRSA)
bacteria. The cobas vivoDx MRSA test uses a new bacteriophage technology based
on bioluminescence to detect MRSA from nasal swab samples in as less as 5 hours
compared to 24-48 hours for conventional culture. The cobas vivoDx MRSA
diagnostic test may allow healthcare professionals to evaluate patients for
colonization with MRSA bacteria more quickly than traditional culture-based
techniques.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/3803
Key players are focused on
development and launch of new methicillin resistant staphylococcus aureus
(MRSA) testing systems in the market which is expected to contribute
significantly to the methicillin resistant staphylococcus aureus (MRSA) testing
systems market growth. For instance, in June 2019, Spindiag, a medtech startup
company based in Germany, announced that it had expanded financing of its first
Series A funding for MRSA testing systems. A proprietary microfluidic
technology was first researched at the company’s main institute. Spindiag is
developing a sustainable platform to diagnose infections and as a first
product, a rapid test for multidrug-resistant bacteria. Furthermore, the
additional money will enable industrializing the production and securing CE-IVD
approval for the EU market of an MRSA (methicillin-resistant Staphylococcus
aureus) rapid test is planned for launch in 2020. Spindiag intends to use US$
4.3 million to execute its market entry in Europe in 2020.
The increasing awareness about
methicillin resistant staphylococcus aureus (MRSA) infections and prevention
efforts by hospitals, governments, and other organizations is expected to
accelerate the methicillin resistant staphylococcus aureus (MRSA) testing
systems market growth in the near future. The U.S. Department of Health and
Human Services and Centers for Disease Control and Prevention are working with
healthcare facilities to meet the goals in the 2013 National Action Plan to
Prevent Healthcare-Associated Infections and reduce bloodstream infections
caused by MRSA by 50% by 2020 using the 2015 baseline.
Browse 35 Market Data Tables and
29 Figures spread through 177 Pages and in-depth TOC on Global Methicillin
Resistant Staphylococcus Aureus (MRSA) Testing Systems Market, By Product
(Instruments, Reagents & Kits), By Test Type (Immunodiagnostic Test, and
Molecular Diagnostic Test), By End User (Hospitals, Diagnostic Laboratories,
and Academic and Research Institute), and By Region (North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa) - Forecast to
2027"
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/methicillin-resistant-staphylococcus-aureus-testing-systems-market-3803
Several market players are
focused on acquisitions and mergers to expand their product portfolio and gain
a maximum share in the market. For instance, in September 2017, Abbott
Laboratories announced that they have completed the acquisition of Alere, Inc. for
US$ 5.3 billion. With the acquisition of Alere, the company also obtained the
subsidiary Arriva Medical, which is the largest mail-order diabetic supplier.
This acquisition has established Abbott as the global leader in point of care
testing in vitro diagnostics market and further strengthened the company's
diagnostics presence.
Key Takeaways of the Methicillin
Resistant Staphylococcus Aureus (MRSA) testing systems market:
The methicillin resistant
staphylococcus aureus (MRSA) testing systems market is expected to exhibit a
CAGR of xx% during the forecast period (2020-2027) owing to increasing product
approvals and product launches.
Among product type, the
instruments segment is expected to hold a major revenue share in 2027 owing to
the increasing product approvals and launches. For instance, in March 2014,
AdvanDx announced that it has submitted its new mecA XpressFISH test to the
U.S. Food and Drug Administration for 510(k) clearance for the rapid detection
of methicillin-resistant Staphylococcus aureus (MRSA) from S. aureus positive
blood cultures. This assay will provide physicians with a new way to rapidly
identify MRSA enabling them to implement appropriate treatment for patients
with bloodstream infections.
Major players operating in the
methicillin resistant Staphylococcus aureus (MRSA) testing systems market are
F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH,
BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, Abbott
Laboratories, Puritan Medical Products, Diatherix Eurofins, LLC, Arlington
Scientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., Luminex
Corporation, and R-Biopharm AG.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/3803
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment